Member Info for Pie-chart

I agree with Porter.

I don't expect new, news at the event.

Clock watching at 7am is never a good idea. Multiple Positive RNS will come this month, I'm sure but maybe near the tail end.

I would like to know what the free float is looking like.

Sorry to hear you sold Marty! Lol!

Going by the LinkedIn post and timeline I think it should be more than gut feeling. Its quite factual.

The fact the AGM hasn't been announced yet has a very bullish interpretation. Ducks being lined up to deliver a bumper update me thinks.

Exactly that Offgrid. |

That'll be why it didn't impact the price.

The ACVIM - American college of veterinary internal medicine congress meeting is held 11–13 June 2026

Will this mean an RNS drops the same week with the positive Methylation Clock results ahead of their announcement at this event...

the bod are doing more than people think. we can **** out good news every 5 minutes. what due in the next 2 months can and likely will, completely change the game for us.

Next month will be a re-rate. 5p plus.

Q3 2026 (Potentially Biggest Data Window)

June–July 2026 — Full 6-Month Dog Study Results

This is likely the single biggest catalyst of the year. The company has consistently guided toward June–July for:

full 180-day efficacy data,

methylation clock results,

muscle histology analysis,

durability assessment.

Bullish scenario:

strong biological age reversal signals,

durable muscle/frailty improvements,

partnership deal follows shortly after.

Bearish scenario:

methylation data weak or inconsistent,

effects not statistically convincing,

enthusiasm fades quickly.

The methylation clock data is especially important because longevity biotech investors tend to treat that as the closest thing to a measurable “anti-aging” biomarker.

Now I'm hungry!

I'm sure they will get revenue from packaging up our MRNA. Its win win. NO soul selling at all.

They supply Veterinary medicines. Much more saturated/competitive market so a 36% rise is good. Genf on the other hand is on track for a 5-10x.

Where they DO overlap:

Both targeting ageing in dogs

Both going after:

Lifespan / healthspan extension

Age-related conditions

Both trying to be early movers in “longevity as a treatable condition”

👉 So yes — there is a shared market emerging: canine longevity

🔬 But the approach is very different

Loyal:

Small molecule drugs (pills)

Targets metabolic pathways (e.g. IGF-1)

Easier to manufacture, scale, and approve

Much closer to market

Genflow:

Gene therapy (SIRT6)

One-time or infrequent treatment (theoretically)

Much more complex scientifically and regulatorily

Earlier stage

👉 Think of it like:

Loyal = “daily anti-ageing pill for dogs”

Genflow = “genetic reprogramming approach”

Short answer: No — Loyal is not a direct competitive threat to Genflow right now.

But there is a longer-term, indirect overlap worth understanding.

Let’s break it down properly.

🧬 What Loyal actually does

Developing longevity drugs for dogs, not humans

Lead product: LOY-002, a daily pill for older dogs

Focus: metabolic & hormonal ageing pathways (e.g. IGF-1, insulin resistance)

Goal: extend healthspan and lifespan by ~1 year in dogs

Already:

Running large clinical trials (~1,000+ dogs)

Has cleared key FDA veterinary milestones

👉 Important: this is veterinary medicine, not human therapeutics.

🧪 What Genflow Biosciences Plc does

Developing gene therapies for humans

Core tech: SIRT6 gene variants

Focus areas:

Longevity

Metabolic disease

Now: muscle ageing (sarcopenia, frailty)

👉 Entirely different:

Modality: gene therapy

End market: human medicine

Stage: earlier than Loyal in clinical terms

Literally*

Laterally any day now this could sky rocket on news due for 1 out of the 5 programmes they are working on.

Also patent news could drop as well as next tranche of funding.

News is not overdue. Its due in April. So no panic.

This is inevitable. It's a must if we want to end up on NASDAQ.

Ideally positive Methyl clock first then the Vet deal will be far bigger.

I wouldn't get caught up in the size of the raise. Don't be surprised if its much more. The bigger the raise the better the bargaining power.

Bring it on!